Phase II study of Neoadjuvant chemotherapy with Gemcitabine and S1 for resectable pancreatic carcinoma

Phase II study of Neoadjuvant chemotherapy with Gemcitabine and S1 for resectable pancreatic carcinoma - Prep-01

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004148

Enrollment

Registered

2010-10-01

Start date

2010-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

resectable pancreatic cancer

Interventions

Neoadjuvant treatment with gemcitabine and S1

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) invasive ductal carcinoma of the pancreas 2) no distant metastasis 3) R0/1 resectable 4) all adult who anticipate to undergo pancreatectomy 5) no prior therapy 6) written informed consent

Exclusion criteria

Exclusion criteria: 1) pulmonary fibrosis or interstitial pneumonitis 2) tumor other than ductal carcinoma 3) distant metastasis 4) R2 resection 5) prior anti-cnacer therapy 6) pregnancy 7) under 20 years old

Design outcomes

Primary

Measure	Time frame
2 year survival rate	—

Secondary

Measure	Time frame
Adverse effect, resectability rate, residual tumor(R), nodal involvement(N), pathological effect, recurrence free survival, tumor marker, dose intensity	—

Countries

Japan

Contacts

Public ContactFuyuhiko Motoi

Tohoku University Hospital Hepato-Biliary Pancreatic surgery

fmotoi@surg1.med.tohoku.ac.jp022-717-7205

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026